[go: up one dir, main page]

RU2010141793A - Терапевтические замещенные циклопентаны - Google Patents

Терапевтические замещенные циклопентаны Download PDF

Info

Publication number
RU2010141793A
RU2010141793A RU2010141793/04A RU2010141793A RU2010141793A RU 2010141793 A RU2010141793 A RU 2010141793A RU 2010141793/04 A RU2010141793/04 A RU 2010141793/04A RU 2010141793 A RU2010141793 A RU 2010141793A RU 2010141793 A RU2010141793 A RU 2010141793A
Authority
RU
Russia
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
compound according
compound
Prior art date
Application number
RU2010141793/04A
Other languages
English (en)
Other versions
RU2501789C2 (ru
Inventor
Ярив ДОНДЕ (US)
Ярив ДОНДЕ
Роберт М. БЁРК (US)
Роберт М. БЁРК
Джеремиа Х. НГУЙЕН (US)
Джеремиа Х. НГУЙЕН
Original Assignee
Аллерган, Инк. (Us)
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. (Us), Аллерган, Инк. filed Critical Аллерган, Инк. (Us)
Publication of RU2010141793A publication Critical patent/RU2010141793A/ru
Application granted granted Critical
Publication of RU2501789C2 publication Critical patent/RU2501789C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

1. Соединение формулы ! ! где Y представляет собой ! или ; ! или его фармацевтически приемлемая соль, ! где пунктирная линия показывает наличие или отсутствие связи. ! 2. Соединение по п.1 формулы ! ! или его фармацевтически приемлемая соль. ! 3. Соединение по п.1 формулы !! или его фармацевтически приемлемая соль. ! 4. Соединение по п.3 формулы ! ! или его фармацевтически приемлемая соль. ! 5. Соединение по п.1 формулы ! ! или его фармацевтически приемлемая соль. ! 6. Способ лечения облысения, включающий введение соединения по п.1 млекопитающему, нуждающемуся в таком лечении.

Claims (6)

1. Соединение формулы
Figure 00000001
где Y представляет собой
Figure 00000002
или
Figure 00000003
;
или его фармацевтически приемлемая соль,
где пунктирная линия показывает наличие или отсутствие связи.
2. Соединение по п.1 формулы
Figure 00000004
или его фармацевтически приемлемая соль.
3. Соединение по п.1 формулы
Figure 00000005
или его фармацевтически приемлемая соль.
4. Соединение по п.3 формулы
Figure 00000006
или его фармацевтически приемлемая соль.
5. Соединение по п.1 формулы
Figure 00000007
или его фармацевтически приемлемая соль.
6. Способ лечения облысения, включающий введение соединения по п.1 млекопитающему, нуждающемуся в таком лечении.
RU2010141793/04A 2008-03-18 2009-03-17 Терапевтические замещенные циклопентаны RU2501789C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3762508P 2008-03-18 2008-03-18
US61/037,625 2008-03-18
US12/404,753 2009-03-16
US12/404,753 US7732443B2 (en) 2008-03-18 2009-03-16 Therapeutic substituted cyclopentanes
PCT/US2009/037355 WO2009117388A1 (en) 2008-03-18 2009-03-17 Therapeutic substituted cyclopentanes

Publications (2)

Publication Number Publication Date
RU2010141793A true RU2010141793A (ru) 2012-04-27
RU2501789C2 RU2501789C2 (ru) 2013-12-20

Family

ID=41089539

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010141793/04A RU2501789C2 (ru) 2008-03-18 2009-03-17 Терапевтические замещенные циклопентаны

Country Status (10)

Country Link
US (1) US7732443B2 (ru)
EP (1) EP2265576A1 (ru)
JP (1) JP2011515406A (ru)
KR (1) KR20100135264A (ru)
CN (1) CN102007098B (ru)
AU (1) AU2009225706B2 (ru)
BR (1) BRPI0910931A2 (ru)
CA (1) CA2718900A1 (ru)
RU (1) RU2501789C2 (ru)
WO (1) WO2009117388A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728227A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic cyclopentane derivatives
US8569349B2 (en) * 2008-05-09 2013-10-29 Allergan, Inc. Therapeutic compounds
US9024042B2 (en) * 2012-08-27 2015-05-05 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
DK3107906T3 (en) * 2014-02-20 2019-03-18 Allergan Inc REDUCED CENTRAL CORNER MAP THICKNESS USING HYDROFILE ESTER PRODRUGS OF BETA-CHLORCYCLOPENTANE
US9340534B2 (en) * 2014-07-25 2016-05-17 Allergan, Inc. Compounds and methods for treating ocular diseases
AU2015327817B2 (en) 2014-10-02 2020-04-23 Allergan, Inc. Ester prodrugs of gamma-lactams and their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4675182A (en) * 1983-02-12 1987-06-23 Bayer Aktiengesellschaft Complexes of prostaglandins
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
CN1617868A (zh) * 2001-11-05 2005-05-18 阿勒根公司 作为EP2-受体激动剂的ω-环烷基17-杂芳基前列腺素E2 类似物
AU2004211936B2 (en) * 2003-02-11 2008-09-11 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
EP2285790A1 (en) * 2008-05-09 2011-02-23 Allergan, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
CA2718900A1 (en) 2009-09-24
BRPI0910931A2 (pt) 2019-09-24
RU2501789C2 (ru) 2013-12-20
CN102007098B (zh) 2014-05-07
KR20100135264A (ko) 2010-12-24
JP2011515406A (ja) 2011-05-19
US20090239869A1 (en) 2009-09-24
US7732443B2 (en) 2010-06-08
EP2265576A1 (en) 2010-12-29
AU2009225706B2 (en) 2014-07-31
CN102007098A (zh) 2011-04-06
WO2009117388A1 (en) 2009-09-24
AU2009225706A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
RU2010141793A (ru) Терапевтические замещенные циклопентаны
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
UA110983C2 (ru) Производная 1,2,3,4-тетрагидрохинолина, пригодная для лечения диабета
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
EA200802213A1 (ru) Способы лечения заболеваний крови
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201270247A1 (ru) Способы применения с-мет-модуляторов
EA201071099A1 (ru) СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
EP4327886A3 (en) Pyrimido- pyridazinone compounds and use thereof
EA200970512A1 (ru) Лечение по поводу множественной миеломы
UA107562C2 (uk) Спосіб лікування псоріазу
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150318